Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast CancerSuzanne E. Wardell, Shunqiang Li, Matthew J. Ellis et al.|Unknown|2023Cited by 0
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast CancerSuzanne E. Wardell, Shunqiang Li, Matthew J. Ellis et al.|Unknown|2023Cited by 0
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast CancerSuzanne E. Wardell, Shunqiang Li, Matthew J. Ellis et al.|Unknown|2023Cited by 0
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast CancerSuzanne E. Wardell, Shunqiang Li, Matthew J. Ellis et al.|Unknown|2023Cited by 0
Suppl. Figure 1 from A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast CancerX. Cynthia, Matthew J. Ellis, César Sánchez et al.|Unknown|2023Cited by 0